Ampoule antidote

The Pfizer Sterile Injectable Business is Positioned for Future Growth

The Pfizer Sterile Injectable business is positioned for future growth as evidenced by our $800 million investment in 2018, and a planned additional investment of up to $1.4 billion in manufacturing capabilities over the next several years. Our first priority is always to provide patients with a consistent and reliable supply of high quality medicines. These investments will help increase our output and mitigate future supply issues.

We are leveraging our extensive Pfizer manufacturing network to increase capacity, often manufacturing products in multiple locations to meet market demand, which has enabled recovery of select molecules this year. We believe we have the capabilities, expertise, resources and talent required to be successful in this marketplace, which is why we're taking an active role in driving sustainability across the injectables market for the long term.

By the end of 2019, we anticipate our supply issues will be significantly improved and on track to become a growth contributor in the future.

Go back

Explore Our Innovation